CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
Recruiting
Observational Study
Neuroendocrine Carcinoma of Lung
Neuroendocrine Carcinoma of Thymus
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 34 (estimated)
- Sponsor
- European Institute of Oncology · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The study involves the enrollment of 34 patients diagnosed with advanced thymic, pulmonary and duodeno-pancreatic well-differentiated high grade neuroendocrine tumors (Ki-67 \> 20%). The objective of this retrospective single-centre translational study will be to explore whether patients differ clinically in terms of diagnosis and treatment management. Currently, well differentiated high grade pul…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Histologically confirmed diagnosis of well-differentiated high grade neuroendocrine tumor (Ki-67 \> 20% according to WHO 2022) performed or reviewed by a NEN-dedicated pathologist.
* Primary tumor site:thyme, lung and duodenum-pancreas NETs.
* Advanced stage of tumor disease a…
Contacts